Download PDF
Thromb Haemost 2023; 123(05): 535-544
DOI: 10.1055/s-0042-1758835
Stroke, Systemic or Venous Thromboembolism

Survival Implications of Thrombus Recurrence or Bleeding in Cancer Patients Receiving Anticoagulation for Venous Thromboembolism Treatment

Robert D. McBane II
1   Gonda Vascular Center, Mayo Clinic, Rochester, Minnesota, United States
2   Department of Cardiovascular, Mayo Clinic, Rochester, Minnesota, United States
,
Danielle T. Vlazny
1   Gonda Vascular Center, Mayo Clinic, Rochester, Minnesota, United States
2   Department of Cardiovascular, Mayo Clinic, Rochester, Minnesota, United States
,
Damon Houghton
1   Gonda Vascular Center, Mayo Clinic, Rochester, Minnesota, United States
2   Department of Cardiovascular, Mayo Clinic, Rochester, Minnesota, United States
,
Ana I. Casanegra
1   Gonda Vascular Center, Mayo Clinic, Rochester, Minnesota, United States
2   Department of Cardiovascular, Mayo Clinic, Rochester, Minnesota, United States
,
David Froehling
1   Gonda Vascular Center, Mayo Clinic, Rochester, Minnesota, United States
2   Department of Cardiovascular, Mayo Clinic, Rochester, Minnesota, United States
,
Paul Daniels
1   Gonda Vascular Center, Mayo Clinic, Rochester, Minnesota, United States
2   Department of Cardiovascular, Mayo Clinic, Rochester, Minnesota, United States
,
Irbaz bin Riaz
3   Division of Hematology, Mayo Clinic, Scottsdale, Arizona, United States
,
David O. Hodge
4   Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, United States
,
Waldemar E. Wysokinski
1   Gonda Vascular Center, Mayo Clinic, Rochester, Minnesota, United States
2   Department of Cardiovascular, Mayo Clinic, Rochester, Minnesota, United States
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints


Abstract

Background Study aims were to analyze prospectively collected data from patients with cancer-associated venous thromboembolism (VTE) to determine the impact of VTE recurrence and anticoagulant-related bleeding on all-cause mortality.

Patients/Methods Consecutive cancer patients with acute VTE treated with anticoagulants (March 1, 2013–November 30, 2021) were included in this analysis. Anticoagulant therapy-associated VTE recurrences, major bleeding, and clinically relevant nonmajor bleeding (CRNMB) were assessed for their impact on all-cause mortality outcomes.

Results This study included 1,812 cancer patients with VTE. Of these, there were 97 (5.4%) with recurrent VTE, 98 (5.4%) with major, and 104 (5.7%) with CRNMB while receiving anticoagulants. Recurrent VTE (hazard ratio [HR]: 1.52; 95% confidence interval [CI]: 1.16–2.00; p = 0.0028), major bleeding (HR: 1.82; 95% CI: 1.41–2.31; p = 0.006), and CRNMB (HR; 1.38; 95% CI: 1.05–1.81; p = 0.018) each adversely influenced mortality outcomes. Deep vein thrombosis as the incident thrombotic event type was associated with VTE recurrence (HR: 1.78; 95% CI: 1.08–2.89; p = 0.02). Neither cancer type nor stage, chemotherapy, or Ottawa risk category influenced VTE recurrence. Higher body weights (HR: 1.01; 95% CI: 1.00–1.01; p = 0.005) were associated with increased major bleeding, while high Ottawa scores (HR: 0.66; 95% CI: 0.46–0.96; p = 0.03) and apixaban treatment (HR: 0.62; 95% CI: 0.45–0.84; p = 0.002) were associated with fewer major bleeding outcomes.

Conclusion Among cancer patients receiving anticoagulant therapy for VTE, adverse outcomes such as VTE recurrence, major bleeding, or CRNMB increase mortality risk by 40 to 80%. Identifying variables predicting these outcomes may help risk-stratify patients with poor prognosis.

Keywords

cancer - venous thromboembolism - anticoagulants - major bleeding - clinically relevant nonmajor bleeding - mortality

Supplementary Material



Publication History

Received: 27 June 2022

Accepted: 18 October 2022

Article published online:
27 December 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160 (06) 809-815
    CrossrefPubMedSearch in Google Scholar
  • 2 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5 (03) 632-634
    CrossrefPubMedSearch in Google Scholar
  • 3 Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343 (25) 1846-1850
    CrossrefPubMedSearch in Google Scholar
  • 4 Chee CE, Ashrani AA, Marks RS. et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood 2014; 123 (25) 3972-3978
    CrossrefPubMedSearch in Google Scholar
  • 5 Trujillo-Santos J, Nieto JA, Ruíz-Gamietea A. et al; RIETE Investigators. Bleeding complications associated with anticoagulant therapy in patients with cancer. Thromb Res 2010; 125 (Suppl. 02) S58-S61
    CrossrefPubMedSearch in Google Scholar
  • 6 Lee AYY, Levine MN, Baker RI. et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (02) 146-153
    CrossrefPubMedSearch in Google Scholar
  • 7 Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J. ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006; 12 (04) 389-396
    CrossrefPubMedSearch in Google Scholar
  • 8 Hull RD, Pineo GF, Brant RF. et al; LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119 (12) 1062-1072
    CrossrefPubMedSearch in Google Scholar
  • 9 Lee AYY, Kamphuisen PW, Meyer G. et al; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015; 314 (07) 677-686
    CrossrefPubMedSearch in Google Scholar
  • 10 Raskob GE, van Es N, Verhamme P. et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
    CrossrefPubMedSearch in Google Scholar
  • 11 Kraaijpoel N, Di Nisio M, Mulder FI. et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer Study. Thromb Haemost 2018; 118 (08) 1439-1449
    Thieme ConnectPubMedSearch in Google Scholar
  • 12 Young AM, Marshall A, Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
    CrossrefPubMedSearch in Google Scholar
  • 13 McBane II RD, Wysokinski WE, Le-Rademacher JG. et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost 2020; 18 (02) 411-421
    CrossrefPubMedSearch in Google Scholar
  • 14 Agnelli G, Becattini C, Meyer G. et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17) 1599-1607
    CrossrefPubMedSearch in Google Scholar
  • 15 Ageno W, Vedovati MC, Cohen A. et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio Study. Thromb Haemost 2021; 121 (05) 616-624
    Thieme ConnectPubMedSearch in Google Scholar
  • 16 Bott-Kitslaar DM, Saadiq RA, McBane RD. et al. Efficacy and safety of rivaroxaban in patients with venous thromboembolism and active malignancy: a single-center registry. Am J Med 2016; 129 (06) 615-619
    CrossrefPubMedSearch in Google Scholar
  • 17 Houghton DE, Vlazny DT, Casanegra AI. et al. Bleeding in patients with gastrointestinal cancer compared with nongastrointestinal cancer treated with apixaban, rivaroxaban, or enoxaparin for acute venous thromboembolism. Mayo Clin Proc 2021; 96 (11) 2793-2805
    CrossrefPubMedSearch in Google Scholar
  • 18 Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8 (01) 202-204
    CrossrefPubMedSearch in Google Scholar
  • 19 Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (11) 2119-2126
    CrossrefPubMedSearch in Google Scholar
  • 20 Louzada ML, Carrier M, Lazo-Langner A. et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 2012; 126 (04) 448-454
    CrossrefPubMedSearch in Google Scholar
  • 21 Lecumberri R, Alfonso A, Jiménez D. et al; RIETE investigators. Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism. Thromb Haemost 2013; 110 (04) 834-843
    PubMedSearch in Google Scholar
  • 22 Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010; 152 (09) 578-589
    CrossrefPubMedSearch in Google Scholar
  • 23 Trujillo-Santos J, Nieto JA, Tiberio G. et al; RIETE Registry, Findings from the RIETE Registry. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Thromb Haemost 2008; 100 (03) 435-439
    Thieme ConnectPubMedSearch in Google Scholar
  • 24 Trujillo-Santos J, Ruiz-Gamietea A, Luque JM. et al; RIETE Investigators, Findings from the RIETE Registry. Predicting recurrences or major bleeding in women with cancer and venous thromboembolism. Thromb Res 2009; 123 (Suppl. 02) S10-S15
    CrossrefPubMedSearch in Google Scholar
  • 25 Trujillo-Santos J, Di Micco P, Iannuzzo M. et al; RIETE Investigators, Findings from the RIETE Registry. Elevated white blood cell count and outcome in cancer patients with venous thromboembolism. Thromb Haemost 2008; 100 (05) 905-911
    Thieme ConnectPubMedSearch in Google Scholar
  • 26 Falanga A, Gal GL, Carrier M. et al. Management of cancer-associated thrombosis: unmet needs and future perspectives. TH Open 2021; 5 (03) e376-e386
    Thieme ConnectPubMedSearch in Google Scholar
  • 27 Shaw JR, Douketis J, Le Gal G, Carrier M. Periprocedural interruption of anticoagulation in patients with cancer-associated venous thromboembolism: an analysis of thrombotic and bleeding outcomes. J Thromb Haemost 2019; 17 (07) 1171-1178
    CrossrefPubMedSearch in Google Scholar
  • 28 Ruíz-Giménez N, Suárez C, González R. et al; RIETE Investigators, Findings from the RIETE Registry. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Thromb Haemost 2008; 100 (01) 26-31
    Thieme ConnectPubMedSearch in Google Scholar